本文转载自长风药业——面向肺气肿的微创介入治疗进入临床验证新阶段2025年10月17日，中国广州— 近日，长风药业股份有限公司（港交所代码2652.HK，以下简称“长风药业”，“公司”）自研支气管活瓣肺减容装置成功完成首例受试者入组（FPI），本临床验证阶段由此正式拉开帷幕，旨在为肺气肿等慢阻肺（COPD）相关人群拓展一条微创介入治疗路径。首例入组手术的顺利完成，标志着此项创新微创介入器械正式进入...
Source Link本文转载自长风药业——面向肺气肿的微创介入治疗进入临床验证新阶段2025年10月17日，中国广州— 近日，长风药业股份有限公司（港交所代码2652.HK，以下简称“长风药业”，“公司”）自研支气管活瓣肺减容装置成功完成首例受试者入组（FPI），本临床验证阶段由此正式拉开帷幕，旨在为肺气肿等慢阻肺（COPD）相关人群拓展一条微创介入治疗路径。首例入组手术的顺利完成，标志着此项创新微创介入器械正式进入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.